作者：
Jeffrey W,Johannes [1]
;
Stephanie,Bates [2]
;
Carl,Beigie [1]
;
Matthew A,Belmonte [1]
;
John,Breen [1]
;
Shenggen,Cao [3]
;
Paolo A,Centrella [4]
;
Matthew A,Clark [4]
;
John W,Cuozzo [4]
;
Christoph E,Dumelin [4]
;
Andrew D,Ferguson [1]
;
Sevan,Habeshian [4]
;
David,Hargreaves [2]
;
Camil,Joubran [1]
;
Steven,Kazmirski [1]
;
Anthony D,Keefe [4]
;
Michelle L,Lamb [1]
;
Haiye,Lan [3]
;
Yunxia,Li [3]
;
Hao,Ma [3]
;
Scott,Mlynarski [1]
;
Martin J,Packer [5]
;
Philip B,Rawlins [2]
;
Daniel W,Robbins [1]
;
Haidong,Shen [3]
;
Eric A,Sigel [4]
;
Holly H,Soutter [4]
;
Nancy,Su [1]
;
Dawn M,Troast [4]
;
Haiyun,Wang [1]
;
Kate F,Wickson [2]
;
Chengyan,Wu [3]
;
Ying,Zhang [4]
;
Qiuying,Zhao [3]
;
Xiaolan,Zheng [1]
;
Alexander W,Hird [1]
作者单位：
AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
[1]
AstraZeneca R&D Cambridge Science Park , Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom.
[2]
Pharmaron Beijing Co., Ltd. 6 Taihe Road BDA, Beijing 100176 P. R. China.
[3]
X-Chem Pharmaceuticals , 100 Beaver Street, Waltham, Massachusetts 02453, United States.
[4]
AstraZeneca R&D Alderley Park , Macclesfield, Cheshire SK10 4TG, United Kingdom.
[5]
DOI
10.1021/acsmedchemlett.6b00464
PMID
28197319
发布时间
2021-01-09
换一批
换一批
